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1. GENERAL OVERVIEW, DEMOGRAPHIC STATISTICS, ECONOMY, AND EDUCATION {#mgg3392-sec-0002}
===================================================================

Tunisia is situated on the northern coast of Africa, bordered by Algeria to the west, Libya to the southeast and the Mediterranean Sea along its northern and eastern sides (Figure [1](#mgg3392-fig-0001){ref-type="fig"}). It is the smallest country in North Africa and covers 163,610.0 sq. km; slightly larger than Georgia (World bank \#92), with 1,148 km of coastline. Tunisia is divided into 24 governorates; the capital Tunis is the smallest and the most populated.

![Map of Tunisia, boundaries and cities (<https://www.britannica.com/media/full/609229/61574>)](MGG3-6-134-g001){#mgg3392-fig-0001}

As of 1 July 2015, the number of inhabitants was 11,154,370 (5,557,966 males and 5,596,404 females), 2.94 times higher since independence (3.78 millions in 1956). About 45% of the population is represented by individuals between the ages of 25 and 54, with a median age of 32.4 years. The growth rate is estimated at 0.86%. The majority of the population occupies the northern and coastal region of the country, with 66.8% living in urban areas.

Because of its strategic location at the crossroads of Europe, Africa and the Middle East, Tunisia witnessed the succession of many civilizations throughout its history. Its population is ethnically heterogeneous, with the presence of the indigenous Berbers together with people from the invading civilizations (Phoenicians, romans, Arabs, and others) as well as from migration.

Formal Arabic is the official language, however, natives speak a dialect of Tunisian Arabic and Shilha is still used by Berbers. French is the language used in most of the institutions; it plays an important role in education and the press. English is currently considered the second foreign language and it is now introduced at the elementary school level. The overwhelming majority of Tunisians (98%) are Muslim, the rest are Christians, Jews, and others.

The Tunisian family size average is 4.1; it is getting smaller in big cities (General population census 2014, National Institute of Statistics). There is prevalence of consanguineous marriages and geographic endogamy, mainly in the more rural areas. Consanguinity rate ranges from 20.1% to 39.33% (Ben Arab, Masmoudi, Beltaief, Hachicha, & Ayadi, [2004](#mgg3392-bib-0019){ref-type="ref"}; Riou, el Younsi, & Chaabouni, [1989](#mgg3392-bib-0185){ref-type="ref"}).

Based on the 2014 statistics, Tunisia is classified in the high development category with a human development index (HDI) value of 0.721 compared to 0.486 in 1980, an increase of 48.4%. Furthermore, the gross national income per capita increased by 101.8%. However, this development is unevenly distributed and is much higher in the eastern coastal regions. Regional inequities are considered the main barrier to socioeconomic development, with more developed coastal regions and an impoverished interior. As per 2010 data, 15.5% of the population is living below the poverty line. Such gaps between the different regions became more evident after the 2011 revolution (Hermassi, [2013](#mgg3392-bib-0119){ref-type="ref"}).

A few years after the revolution, Tunisia\'s economy remains weak, with a high unemployment rate (17.6%); particularly among young people and university graduates where it reaches 37.6%. This situation led to labor emigration mainly to European countries. Bilateral labors agreements were signed with a number of these countries with the expectation that these young workers will later return home. Unfortunately, the lack of job creation in Tunisia together with skill mismatches and the imposed restriction of immigration by European countries created a massive illegal migration flow (mainly to Europe). Furthermore, this situation worsened following the Civil war in Libya as around 1.8 million Libyans have fled to Tunisia.

Just after the independence, our first president, Habib Bourguiba, enacted a law that allows all inhabitants to have access to free schools regardless of their religion, sex or race. Later, in 1991, the first 9 years of schooling became compulsory and education was established as a national priority. However, the government does not mandate preschool, and most of the facilities are private.

In 2008, the World Bank reported that 96.79% of people between the ages of 15 and 24 were literate, which provides a strong foundation of hope for the future of literacy in Tunisia. The rate of illiteracy among women was somewhat higher than that among men.

The 2014 data showed that 32.8% of adult Tunisian women have reached at least a secondary level of education compared to 46.1% of their male counterparts. The report showed that 31.3% of parliamentary seats are hold by women, compared to only 14% in Arab states. However, female participation in the labor force is much lower compared to men (25.1 versus 70.9%).

The education system in Tunisia is recognized as one of the most modernized in the region. Several laws were instated to help with the integration of special needs students. However, not enough specialized centers to help patients with developmental and cognitive delays are offered and the increase in the number of integrative schools was paralleled by an increase in enrolled students. Furthermore, there is a lack for trained professionals that can meet the needs of these patients. UNICEF data showed that 90% of teachers in integrative schools are not prepared to teach special education and did not receive any formal and specific training (Shaub, [2016](#mgg3392-bib-0191){ref-type="ref"}).

2. TUNISIA: FROM THE STONE AGE TO THE PRESENT ERA {#mgg3392-sec-0003}
=================================================

Evidence of Paleolithic settlement was found in different archeological sites in Tunisia, one of the oldest being Sidi Zin in the Northwest of the country (Gragueb, [1980](#mgg3392-bib-0096){ref-type="ref"}). Excavated by Gobert in 1950, the site of Sidi Zin is located 11 km south of the city of Kef, and is particularly known for its Acheulian levels. Artifacts from the Mousterian level, characteristic of the middle Paleolithic, were also found and included small bifaces, sidescrapers, and thick points (Aouadi‐Abdeljaouad & Belhouchet, [2012](#mgg3392-bib-0012){ref-type="ref"}). During recent excavations by Tunisian and British researchers near Tozeur, in the southwest of the country, flint tools---among other artifacts---were discovered and reported to be the oldest evidence of human activity in Tunisia (92,000‐years old). Bones indicating the presence of savannah animals and therefore fresh water were unearthed.

The excavation of the Aïn El‐Guettar Mousterian site, located approximately 15 km southeast of Gafsa, yielded a faunal assemblage dominated by bovids and equids. The site was associated with a lithic industry with Levallois technology (Aouadi‐Abdeljaouad & Belhouchet, [2008](#mgg3392-bib-0011){ref-type="ref"}; Gruet, [1954](#mgg3392-bib-0099){ref-type="ref"}). The same site also showed the presence of the Aterian, another Middle Stone age culture. The Aterian industry is based mostly of flakes, Levallois techniques, scrapers and racloir tools. The earliest Aterian sites are believed to be well over 40,000‐year old (Frigi, Cherni, Fadhlaoui‐Zid, & Benammar‐Elgaaied, [2010](#mgg3392-bib-0093){ref-type="ref"}). Furthermore, stone tools were found in the northern and central coastal areas of Tunisia going back to the Aterian civilization.

Small flint tools of around 20,000 BC were attributed to a new culture that became the precursor to North Africa\'s Iberomaurusian civilization (18,000 to 8,000 BC). Small retouched blades, backed bladelets, simple endscrapers, geometrical pieces, among other artifacts were found in the site of Ouchtata, northwest of Tunisia.

The Iberomaurusian people belonged to the Mechtoid anthropological type, also known as Mechta el‐Arbi or Mechta‐Afalou that inhabited the region during the late Paleolithic and Mesolithic. The Iberomaurusian culture was thought to have emerged either as a result of the migration of Cromagnoids from the Iberian Peninsula, or from the local Aterian culture (Ferembach, [1985](#mgg3392-bib-0090){ref-type="ref"}).

During the Holocene, the Capsian civilization covered the period between 10,000 and 7,500 BP. This culture was discovered during the excavation of the site of El‐Mekta, located by Boudy in 1906 on the eponymous hill, 10 km north of Gafsa in southwest Tunisia (Morales et al., [2015](#mgg3392-bib-0164){ref-type="ref"}) (Figure [2](#mgg3392-fig-0002){ref-type="fig"}). Archeologists were able to find stone and bone tools, shell beads and decorated bones, ostrich shell containers, as well as stylized women\'s heads carved from limestone. The Capsians left shell heaps near their dwellings, indicating that snails were an important part of their diet. Evidence for hunting, fishing, food processing and cooking was also abundant. Remains of Aleppo pine as well as Acorns were the commonly detected in the plant assemblage recovered from site El‐Mekta (Morales et al., [2015](#mgg3392-bib-0164){ref-type="ref"}).

![Overview of the open‐air Capsian site "EL‐Mekta"](MGG3-6-134-g002){#mgg3392-fig-0002}

Capsians might be the immediate ancestors of Berbers (Rahmani, [2004](#mgg3392-bib-0179){ref-type="ref"}). The later Neolithic people possibly introduced the Afro‐Asiatic languages (Arredi et al., [2004](#mgg3392-bib-0013){ref-type="ref"}; Sanchez‐Mazas, [2000](#mgg3392-bib-0190){ref-type="ref"}). The indigenous Berbers of Tunisia are called "Amazigh" which means "free people".

During the historical period, the first important invasion was that of the Phoenicians, ancestors of present‐day Lebanese, who used their maritime expertise to establish trading posts in many cities across the Mediterranean (Zalloua et al., [2008](#mgg3392-bib-0211){ref-type="ref"}). In the eigth century B.C (around 814 BCE), after she fled from her brother Pygmalion, king of Tyre (what is today Lebanon), Elissa, also known as "Dido", and her followers established the colony of "Kart‐Hadasht" (latin Carthago) known as "Carthage" and meaning "New City". Carthage later became the greatest naval power of the Mediterranean. The temple of Eshmun, the Punic god of healing, was at that time built on the peak of Byrsa Hill, the highest point in the city of Carthage. During the Roman Empire, a cathedral (known now as Saint Louis Cathedral) was built atop of its ruins.

All we know about the Phoenicians is through Greek and Roman sources, since all evidence was destroyed and the Carthaginian literature was lost. Recently, a Punic burial crypt was accidentally discovered by gardeners while planting a tree at the front of the National Museum of Carthage, situated on Byrsa Hill, at the site of the Phoenician acropolis (<http://www.inp.rnrt.tn/index.php?option=com_content&view=article&id=75:jeune-homme-de-byrsa&catid=3>: activites&Itemid=7&lang=en). The skeletal remains of a young man along with funerary goods were found, all dated to the late sixth century BC (Morel, [2011](#mgg3392-bib-0165){ref-type="ref"}). DNA extracted from a small bone sample was used for the first complete ancient Phoenician mitochondrial genome study. An international team of researchers showed that the mitochondrial genome of this "young man of Byrsa" belongs to the haplogroup U5b2c1, a European derived haplotype absent in North Africa and in Lebanese (Matisoo‐Smith et al., [2016](#mgg3392-bib-0152){ref-type="ref"}). Data from other remain throughout the Mediterranean will help us understand the origin of Phoenicians and trace their migrations.

Following the third Punic war (149--146 BCE) between the Romans and Phoenicians, the Roman Empire became the most powerful force in the Mediterranean region and the region was completely Latinized and Christianized. The Vandals, a Germanic tribe, later succeeded Romans; they reigned for almost a century before falling to the armies of Byzantines in 533 AD (Brett & Fentress, [1997](#mgg3392-bib-0057){ref-type="ref"}).

By the end of the seventh century A.D, the Islamic invasion of North Africa was carried by armies from the Arabian Peninsula (Lapidus, [2002](#mgg3392-bib-0137){ref-type="ref"}). They founded the city of Kairouan, about 90 miles south of Carthage, and they spread Islam as well as the Arabic language in the region. Fatimids' invasion then followed in the 11th century AD. The Ottomans then ruled Tunisia for over 400 years.

During the 16th and 17th centuries, epidemic waves, cricket invasions, and starvations led to the death of thousands of individuals. Tunis was then affected by the plague for 19 years; nearly 1,000 individuals died because of epidemics of plague, cholera and typhus in 1918.

As the Ottoman Empire declined, the Berlin Congress of 1878 convened to discuss the future of the North African provinces. As a result, Britain acquiesced to France\'s control of Tunisia and in exchange took over Cyprus. In 1881, the French sent their troops to invade Tunisia and imposed the treaty of Bardo. In 1883, the Bey of Tunis signed an agreement that made Tunisia a French protectorate. It is not until 1956 that Tunisia got her independence from France and became a republic under the leader Habib Bourguiba. On 25 July, 1957, a republic was declared and Bourguiba became the first president of Tunisia. In November 1987, his appointed first prime minister "Ben Ali" removed him from power after a bloodless coup. The latter stayed in power for 23 years until the Tunisian revolution and the collapse of the regime on 14 January 2011. On 27 January 2014, the new president signed the latest approved constitution replacing the one instated in 1959 and amended in 1988 and 2002. The country is still recovering after this political unrest and the violence threatening economic progress.

3. POPULATION DIVERSITY {#mgg3392-sec-0004}
=======================

Although Berbers are the autochthonous inhabitants of the country, the major historical settlements had a crucial impact on the genetic structure and diversity of the current population. As a result, the latter derives its origins from Phoenicians, Romans, Vandals, Byzantines, Africans, Arabs, Turks, Europeans as well as immigrants. Despite all these historical admixtures, some genetic isolates still exist. The best example is the inhabitants of Jerba, an island in the South‐East of Tunisia (Loueslati et al., [2006](#mgg3392-bib-0142){ref-type="ref"}).

To determine the degree of heterogeneity of this population, analysis of 16 Alu and 3 Alu/STR compound systems was carried on 268 healthy unrelated individuals originating from the north‐center and the south regions. Similar levels of gene diversity were found in both groups. Interestingly, the northern sample showed higher frequencies of Berber and sub‐Saharan African‐specific combinations than the southern sample (El Moncer et al., [2010](#mgg3392-bib-0083){ref-type="ref"}). An indication of sub‐Saharan gene flow was also shown by a previous mtDNA haplotype data (Turchi et al., [2009](#mgg3392-bib-0206){ref-type="ref"}).

Trans‐Saharan trade is believed to be the main source of the African flow to the region, although few came from the Arab invasions and from Europe during the colonization of the Maghreb (Northwest Africa). South Tunisia constituted the gateway for Arab tribes invading North African cities. Archeological and historic records suggest that such migration is ancient and could be traced back to 9000 years BP, characterized by an ethnic contribution from present‐day Sudan (El Moncer et al., [2010](#mgg3392-bib-0083){ref-type="ref"}).

According to the official census in 2014, the population living in the south of the country comprises Berbers, Black people, Jews, and Arabs. Most of the studies agreed that the southern Tunisians are native Berbers that were later Arabized during the Arab invasions in the 11th century (Hajjej et al., [2006](#mgg3392-bib-0111){ref-type="ref"}; Hajjej, Sellami, et al., [2011](#mgg3392-bib-0112){ref-type="ref"}).

In an effort to trace the origin of the southern population, a recent "anthropological" study of 250 unrelated Southern Tunisians was conducted using HLA typing, commonly used to track human migrations (Fernandez Vina et al., [2012](#mgg3392-bib-0091){ref-type="ref"}). Data were compared to those of other Tunisians, Middle Eastern Arab‐speaking individuals along with Mediterranean and sub‐Sahara African populations. DRB1\*07:01--DQB1\*02:02 was found to be the most frequent haplotype in Southern Tunisians (18.02%). This haplotype was also present in Tunisian Berbers (16.03%) (Hajjej, Almawi, Hattab, El‐Gaaied, & Hmida, [2016](#mgg3392-bib-0109){ref-type="ref"}). In fact, the HLA class II allele DRB1\*07:01 was present at 22.06% in the southern population, and was detected at high frequencies in Tunisian Berbers (17.6%) and in Ghannouchians (28.7%) occupying a village situated at the eastern south of Tunisia and characterized by high endogamy, behaving like an isolate (Hajjej, Hajjej, et al., [2011](#mgg3392-bib-0110){ref-type="ref"}).

Following the Arab invasion of Tunisia, Berbers migrated to the south and populated the mountainous regions to escape persecution. This resulted in a low admixture between them and the Arab tribes. This fact was further confirmed by the HLA typing data that demonstrated the low contribution of Arabs to the southern genetic pool (Hajjej et al., [2016](#mgg3392-bib-0109){ref-type="ref"}).

A Y‐chromosome lineage analysis was carried on 94 individuals from three Northern and southern Berber‐speaking isolates. Two of the isolates exclusively carried the haplogroup E1b1b1b, also found in other Berber‐speaking groups in North Africa. These two groups lived in the mountains, and historically escaped persecution by the Arab tribes "Banu Hilal and Banu Soulaym" around 1048 AD. Haplogroup J (subtype J1e), previously associated with the Islamic expansion, was found in 31.4% of the third Berber group, living in the plains, indicative of genetic admixture and gene flow from the Near East. However, and in contrast to the mtDNA studies findings, the Y‐chromosome data did not show any evidence of sub‐Saharan African paternal lineages (Fadhlaoui‐Zid et al., [2004](#mgg3392-bib-0087){ref-type="ref"}, [2011](#mgg3392-bib-0086){ref-type="ref"}).

Another study investigating the profile of HLA class I and class II genes was carried on a total of randomly selected 376 unrelated Tunisians originating from the North, South and center of the country. A\*02:01(16.76%) and DRB1\*07:01 (19.02%) alleles, both present at high frequency in Berbers, were found to be the most frequent alleles. Common haplotypes found in Tunisians were also seen in Western Mediterranean populations. There was no evidence of an effect of the Arab invasions (7th and 11th centuries AD) on the genetic makeup of the Tunisians including the autochthonous Berbers. This suggests that no or minimum admixtures occurred between Berbers and Arab tribes. One possible explanation can be the modest number of Arab invaders during the 7th century. Moreover, establishment of settlements did not follow this invasion. Haplotype studies showed that the current inhabitants of the country are closely related to Iberians (Basques and Spaniards) as well as to North Africans but not to Eastern Arabs (Hajjej, Almawi, Hattab, El‐Gaaied, & Hmida, [2015](#mgg3392-bib-0108){ref-type="ref"}).

Following the Bizerte crisis with France and the 6‐day War of 1967, thousands of Jews fled the country. Nowadays, Tunisian Jews constitute less than 0.1% of the total population (1,500); they are mainly clustered in the island of Jerba. Although they constitute a distinct branch, North African Jews showed a significant relatedness to European and Middle Eastern Jews. The Jews from Jerba and the rest of Tunisia were highly endogamous, with very low level of admixture with Arab and Berber inhabitants as shown by Y‐chromosome studies (Campbell et al., [2012](#mgg3392-bib-0058){ref-type="ref"}). It is believed that the first evidence for Jews in North Africa goes back to 312 BCE when King Ptolemy of Egypt settled Jews in the cities of Cyrenaica in current‐day Libya. Historians also reported that in 70 CE, the Roman Emperor Titus destroyed the Great Temple of Jerusalem leading to the deportation of 30,000 Jews to Carthage in present‐day Tunisia. Others traced the origins of Jews in Tunisia to Andalus and Levant (Lucette & Abraham, [1991](#mgg3392-bib-0143){ref-type="ref"}). Following the Arab invasion, some Jewish communities remained in the country but were subject to civil and religious suppression resulting in the high degree of endogamy.

4. HEALTHCARE COVERAGE IN TUNISIA {#mgg3392-sec-0005}
=================================

The newly drafted constitution in 2014 placed national health care at a higher priority and "proclaimed health as a human right and required national healthcare coverage for the poorest of Tunisians" under Article 38.

Since its independence in 1956, Tunisia made health care free for all through a government‐funded system. Four years later, a social protection system with a health insurance scheme and a subsidized care was implemented.

In 1996, the implementation of "large scale reform" was intended to improve coverage and accessibility to healthcare (Achour, [2011](#mgg3392-bib-0005){ref-type="ref"}). Several insurance plans covering different professional groups were merged under the "social security Fund". The benefit package was also extended to include providers in the private sector. Furthermore, an optional complementary health insurance managed by mutual health insurance companies was also introduced. Following the 2004 reform, Tunisia\'s National Health Insurance Fund "CNAM" (Caisse nationale d\'Assurance maladie) was created, aiming to provide universal health coverage for those affiliated with national insurances (CNSS and CNRPS). Coverage was extended to include inpatient and outpatient services provided by the private sector. In late 2007, CNAM introduced a reimbursement scheme also called the "two sector scheme", where beneficiaries can use either public or private providers but are required to first pay then request reimbursement from the CNAM (Makhloufi, Ventelou, & Abu‐Zaineh, [2015](#mgg3392-bib-0145){ref-type="ref"}). Such reform has raised the coverage from 54.6% in 1995 to 88% in 2008 (Abu‐Zaineh, Romdhane, Ventelou, Moatti, & Chokri, [2013](#mgg3392-bib-0004){ref-type="ref"}).

The current health insurance coverage consists of two main insurance schemes, a formal mandatory health insurance (MHI), currently run by CNAM, and a state‐subsidized medical assistance scheme (MAS). The MHI covers the public and the private sector employees as well as self‐employed workers. Most of those ineligible for MHI scheme are entitled to MAS, publicly funded and managed by the Ministry of Social Affairs. Individuals living on the poverty line or earning the minimum wage rate are entitled to receive "Free medical cards" or a "reduced‐fee plans" respectively, both accepted by public sector healthcare services.

Data from the Tunisian HealthCare Utilization and Morbidity Survey showed that 66% of the population are covered by MHI, 22% benefit from MAS, while about 12% remains without access to health insurance coverage (National institute of public health 2008). In recent years, a few private insurance schemes were developed but only benefited a small portion of the population (Abu‐Zaineh et al., [2013](#mgg3392-bib-0004){ref-type="ref"}).

Recent data showed that the Tunisian household spend a lot of money on healthcare, and the average out of pocket payments represented almost 45% of the total health expenditure in 2010 (Chahed & Arfa, [2014](#mgg3392-bib-0063){ref-type="ref"}). Furthermore, although CNAM partially covers birth‐related health expenses at private facilities, it does not cover costs related to premature births, which are much higher.

Although the health insurance package allows the enrollees to use providers from private and public facilities, and despite the existence of two insurance schemes, the system has its flaws. The reimbursement mechanisms limit coverage for a predetermined list of chronic illnesses and surgical interventions, and reimbursement is subject to an annual expenditure capita per household. Moreover, the public facilities are underfunded; in particular, after 2011, many medications and lab tests are not available, and the number of specialist and doctors is insufficient outside big cities and coastal regions. In addition and because of the limited budget of these facilities and the inefficient management, most of the equipment is not serviced and never replaced. On the other hand, the private sector entails high copayments and extra fees making it impossible for a large number of inhabitants to afford it.

5. HEALTH SYSTEM ORGANIZATION {#mgg3392-sec-0006}
=============================

Since 1982, the country implemented a large network of primary health care centers. Currently, health care services are provided by three different sectors: public, private, and parastatal.

Based on the national Statistics Institute and the Ministry of Public Health (MoPH), there are currently 14 general hospitals, 22 Institutes, centers and specialized hospitals mainly located in the large urban cities, 36 regional hospitals providing secondary care, 110 public district hospitals (PDHs), and 2,123 basic health centers. The public health infrastructure is expanding; as such new projects are underway including a second University Hospital in Sfax and another four hospitals or centers planned.

The private sector is the second provider of health care in the country. As of 2014, it operates 82 clinics, with 7,283 medical offices. The parastatal sector is managed by other public departments such as the social security fund (SSF), operates four hospitals, representing 2.5% of hospital beds, six polyclinics, and nine healthcare facilities offering in‐house medical services.

MoPH manages all of the public sector facilities, comprising 85% of total hospital beds and more than 55% of medical personnel (Abu‐Zaineh et al., [2013](#mgg3392-bib-0004){ref-type="ref"}). Public hospitals receive 55% of total outpatient and inpatient care in the country (Ministry of health. Annual Statistical book of hospital\'s indicators. Tunisia: Department of publics' Hospital; 2011).

Despite the increase in the number of hospitals and clinics, about 69% of the total hospital capacity is concentrated in the eastern coastal region of the country. Because of these striking regional differences, many areas have no access to medical services. In 2012, hospital bed density reached 2.1 per 1,000 (Ministry of health, MoH). Overall, the average medical doctor\'s density is about 1.1 per 1,000, however, it is remarkably uneven, ranging from 3.3 to 3.5 doctors for every 1,000 people in the governorates of Tunis, Sfax and Medinine to 0.2 to 0.4 in the south of the country.

In 2014, the total expenditure of Tunisian healthcare system was about 7% of GDP (gross domestic product). Although it is covering 80% of the population, the public sector receives only 20% of the total health expenditures, while the private facilities benefit from 60%.

6. HEALTH SERVICES AND COVERAGE INDICATORS {#mgg3392-sec-0007}
==========================================

Just after the declaration of independence in 1956, the "Code of Personal Status" was instituted. These laws were one of the most revolutionary in the Arab and Islamic world. Tunisia was the first country in the region to abolish polygamy. The law also ensured the right to equal pay for men and women. Since 1959, Tunisian woman received the right to vote and to stand for election.

The right to use contraceptives was protected under law since 1961. A family planning program was instituted in 1966, raising the legal age of marriage and providing free access to contraception and counseling for all women throughout the country. Contraceptive usage rate was estimated at 62.5% in 2012 (WHO). First in Africa, this plan also aimed to slow the population growth. The fertility rate is one of the lowest in the region, decreasing from seven children per woman in 1960 to only two currently (CIA world factbook: <https://www.cia.gov/library/publications/the-world-factbook/geos/ts.html>). The National Board for Family and Population was later created in 1973, and abortion was legalized for any woman within the first trimester regardless of husband\'s approval (Hajri, Raifman, Gerdts, Baum, & Foster, [2015](#mgg3392-bib-0113){ref-type="ref"}).

Reproductive health services are provided mainly by a network of 2,091 primary health care centers, 36 reproductive health centers, and 20 youth centers \[Ministère de la Santé, Direction de la Santé et de la Planification, *Carte sanitaire 2011* (Tunis: Ministère de la Santé, May 2013)\]. However, they are unevenly distributed between the remote rural areas and more industrialized regions. For more detailed information, please refer to the following site: <http://www.santetunisie.rns.tn/images/articles/csfinale2011.pdf> Since 2001, primary health care services include prevention and treatment of sexually transmitted infections with free and confidential HIV tests; furthermore, antiretroviral drugs are freely provided.

During the last 50 years, Tunisia made big progress in increasing life expectancy and decreasing infant mortality. The average life expectancy was 74.9‐year old in 2014 (73.9 for men and 77.4 for women) with an increase by 12.8 years compared to 1980 (Human development report 2015: <http://www.factfish.com/statistic-country/tunisia/human%20development%20index>). A decline of infant mortality rate (before reaching 1 year of age) was achieved, decreasing from 178.7 per 1,000 in 1962 to 51.4 per 1,000 in 1985, and to an estimated 12.1 per 1,000 live births currently. Such rates are two times higher in the rural areas than in the urban ones. In 2015, WHO reported a neonatal mortality rate of 8.2 \[5.8--11.4\] compared to 16.1 \[13.5--19.0\] in 2002.

Reproductive health is measured by maternal mortality and adolescent birth rates. For every 100,000 live births, 46 women die from pregnancy related causes, this marks a striking improvement compared to 131 per 100,000 in 1990. Deliveries attended by skilled personnel reached 97.6% in 2013, compared to only 76.3% in 1990. Adolescent birth rate is estimated at 4.6 births per 1,000. The current birth rate is 16.4 births per 1,000 while the death rate is 5.7 per 1,000 inhabitants, 2,411 stillbirths were reported (<https://knoema.com/atlas/Tunisia/Infant-mortality>).

The incidence of tuberculosis is estimated at 35 per 100,000 people in 2014. This number includes new pulmonary, smear positive, and extrapulmonary tuberculosis cases (Knoema data). Unlike other North African countries, Tunisia has no malaria and only a few cases of HIV. Increased vaccinations among youth led to the almost complete eradication of polio, measles, and neonatal tetanus. In recent years, the life expectancy at birth has increased with 3% of deaths being due to communicable diseases while noncommunicable diseases accounted for 72% of deaths. (<http://www.borgenmagazine.com/strengthening-tunisias-healthcare-system/>).

The population in Tunisia is now aging. With a change in the life style, the burden has shifted from infectious diseases to the emergence of noncommunicable and chronic diseases (hypertension and diabetes) as well as injuries. The top three causes of mortality are ischemic heart disease, cancers and respiratory tract diseases. An increased prevalence of obesity was recorded, with a rate of 27.1% in adults in 2014 (CIA factbook).

Breast cancer and cervical cancer screening have also been introduced into basic health care services as part of the country\'s National Cancer Control Plans.

\[Ministère de la Santé, Direction de Santé, *Plan pour la lutte contre le cancer 2015--2019* (Tunis: Ministère de la Santé, 2015).\]

Tunisia counts 12 officially registered transplant centers (<http://www.transplant-observatory.org/>). The first organ transplantation surgery was performed in 1986 (kidney transplants); since then transplants extended to other organs including cornea, heart, liver, lungs, and pancreas. Tunisia is one of two Arab countries where heart transplants are practiced.

7. GENETIC SERVICES {#mgg3392-sec-0008}
===================

Several centers across the country offer genetic testing and counseling services, however, they are insufficient, do not cover all the regions of country and are far from being comprehensive. The main three genetic clinics are located in the following hospitals located at three coastal cities: Charles Nicolle hospital in the Capital Tunis, Farhat Hached hospital at Sousse, and Habib bourguiba hospital at Sfax.

Very recently, a new unit for congenital and inherited diseases was created at the "Mongi Slim hospital" at Al Marsa where cytogenetic services are also provided. Furthermore, genetic services are also offered as part of research at different centers and at Universities. The main ones are at Pasteur Institute and at the National Neurology Institute. There are few private genetic laboratories with two in Tunis and one in Sfax.

Premarital genetic counseling is mandatory for all couples with family history of genetic diseases and/or consanguinity. This program was implemented in 1964, and then generalized and made mandatory for the entire Tunisian territory in 1995. It was intended to prevent the spread of contagious diseases and limit the frequency of congenital and hereditary diseases in the next generation. It is also an educational program for the future parents, providing information concerning contraception, pregnancy, vaccination, prevention, and counseling. These premarital tests are provided free of charge if done in the public facilities.

Prenatal and postnatal services are available. Fetal ultrasound screening is routinely performed during pregnancy although it is only mandatory during the first trimester. Reliable detection of fetal anomalies relies on how well trained the operator is and how accurate the equipment is. Unfortunately, both criteria are lacking in health facilities in rural areas.

Prenatal diagnosis of chromosomal disorders was available since 1989. Both chorionic villous sampling and amniocentesis are routinely performed upon request and for at‐risk pregnancies. Advanced maternal age is one of the most common reasons for such invasive procedures. It is offered free of charge as a public service, but it is not mandatory and it is up to the couple to decide if they want to get it.

Unfortunately, women living in the more rural and thus poorer areas have less access to prenatal services, monitoring and postnatal follow‐up. According to the WHO 2008 report, "approximately 75% of maternal mortality was due to avoidable causes". Fetal and neonatal outreach programs should be implemented, especially in less‐favored regions in the country. Tunisia does not have an established national screening program for carriers; such service is mainly done on a research basis.

8. GENETIC DISORDERS IN TUNISIA {#mgg3392-sec-0009}
===============================

Genetic disorders constitute a real public health problem and lead to economic and social disadvantages. They constitute a significant burden for the family as well as the healthcare system.

More than 400 genetic disorders were recently assessed in Tunisia. Congenital malformations and chromosomal abnormalities constitute 30% of all genetic disorders found in the Tunisian population, followed by endocrine and metabolic disorders (19%) and nervous system disorders (11%) (Romdhane & Abdelhak, [2011](#mgg3392-bib-0186){ref-type="ref"}). Because of the high consanguinity rates, an estimated sixfold increase risk of autosomal recessive (AR) diseases was previously reported (Ben Halim et al., [2013](#mgg3392-bib-0020){ref-type="ref"}). A recent retrospective study including 425 Tunisian patients with AR disorders detected consanguinity in 69.4% of the cases with a prevalence of first cousin marriages of 48.94%. Consanguinity reaches 65.26% in some southern regions. Most of the mutations were found in the homozygous state. Moreover, geographic endogamy was observed in 93.92% of the cases studied. The authors estimated a sevenfold increase in AR diseases associated with consanguinity; this risk was about 24‐fold in certain cases (Ben Halim et al., [2016](#mgg3392-bib-0021){ref-type="ref"}).

Autosomal dominant disorders represent 23% of all genetic disorders reported in the country, while 5.4% are X‐linked (Romdhane & Abdelhak, [2011](#mgg3392-bib-0186){ref-type="ref"}). More than one genetic condition per family, referred to as comorbidity, was also recently reported (Romdhane et al., [2016](#mgg3392-bib-0188){ref-type="ref"}).

A recent study showed that in Tunisian patients, among 174 genetic diseases with identified molecular defect, 73 (41.9%) were founder mutations. For the majority of them, geographic distribution is limited to a region of the country (Romdhane et al., [2012](#mgg3392-bib-0187){ref-type="ref"}). As an example, the deletion identified in *IL12B* in patients with Mendelian susceptibility to mycobacterial disease (MSMD) is only present in the village of Akouda in central Tunisia (Governorate of Sousse) as shown by haplotype analysis (Ben‐Mustapha et al., [2014](#mgg3392-bib-0045){ref-type="ref"}; Elloumi‐Zghal et al., [2002](#mgg3392-bib-0085){ref-type="ref"}).

Identification of founder mutations facilitates the diagnosis of most common diseases at a reduced cost. Besides early diagnosis, it also provides an opportunity for genetic counseling for future pregnancies and thus disease prevention.

The Mediterranean Founder Mutation Database (MFMD: <http://mfmd.pasteur.ma/>) is a great online resource providing information for 383 founder mutations found in 210 genes related to 219 diseases reported in the Mediterranean population (Charoute et al., [2015](#mgg3392-bib-0068){ref-type="ref"}). Another resource is "The Catalogue for Transmission Genetics in Arabs "CTGA" database", which provides a breadth of information about mutations found in a number of Arab countries (Tadmouri, Al Ali, Al‐Haj Ali, & Al Khaja, [2006](#mgg3392-bib-0193){ref-type="ref"}). Large consanguineous families contributed to the identification of causative loci/genes of a number of AR diseases. Homozygosity mapping in Tunisia was first used to localize Friedreich ataxia with selective vitamin E deficiency locus to chromosome 8q (Ben Hamida et al., [1993](#mgg3392-bib-0023){ref-type="ref"}). Other studies are listed later in this paper.

9. HEMOGLOBINOPATHIES AND OTHER BLOOD DISORDERS {#mgg3392-sec-0010}
===============================================

Hemoglobinopathies are the most common genetic disorders in Tunisia, and pose a major public health problem. Carrier frequency was estimated at 4.48%, although it can reach 12.5% in some at‐risk regions. The frequency of β‐thalassemia trait was about 2.21% while the frequency of hemoglobin S carrier was estimated at 1.89% (Fattoum, [2006](#mgg3392-bib-0089){ref-type="ref"}; Ouali et al., [2016](#mgg3392-bib-0174){ref-type="ref"}). Similarly, another study reported an average frequency of 1.9% for sickle cell disease in the country (Anwar, Khyatti, & Hemminki, [2014](#mgg3392-bib-0010){ref-type="ref"}). Thalassemia and sickle cell disease are reported to be epidemic especially in the North West of the country (Haj Khelil et al., [2004](#mgg3392-bib-0107){ref-type="ref"}, [2010](#mgg3392-bib-0106){ref-type="ref"}). Such high frequencies were mainly due to the positive selection pressure following the malaria epidemic that ravaged the early farmers. Infected mosquitoes were attracted by the soft and marshy soil leading to an epidemic and the emergence of disorders like sickle cell disease, beta thalassemia, and glucose‐6‐dehydrogenase deficiency (G6PD) (Tadmouri, Sastry, & Chouchane, [2014](#mgg3392-bib-0194){ref-type="ref"}). Statistics about other hemoglobinopathies in Tunisia can be found on the ITHANET portal (<http://www.ithanet.eu/db/ithagenes>). ITHANET is a network covering thalassemias as well as other hemoglobinopathies, combining international clinical and research expertise and comprising 26 organizations from 16 countries, including Tunisia (Lederer et al., [2009](#mgg3392-bib-0140){ref-type="ref"}).

Prenatal diagnosis of hemoglobinopathies was first made available in 1986 at the laboratory of biochemistry and molecular biology at children\'s hospital of Tunis, but was only fully functional in 1994. Recently, prenatal diagnosis data for 18 years of experience (1994--2012) was reported. Of 461 fetuses of 340 at‐risk couples, 121 were affected. 41% were at risk for beta thalassemia major while 40.3% were at risk for sickle cell disease. A high consanguinity rate among the affected was noted, and a total of 13 β‐thal mutations were identified. The mutation spectrum revealed a great molecular heterogeneity in Tunisia, with more than 28 different alleles reported to date (Chouk et al., [2004](#mgg3392-bib-0078){ref-type="ref"}; Sahli et al., [2016](#mgg3392-bib-0189){ref-type="ref"}).

G6PD is the most prevalent enzyme deficiency. It is classified into five classes depending on the residual enzyme activity and clinical severity in accordance with the World Health Organization. A previous survey of the Tunisian population has estimated the incidence of the deficiency at 4%. However, a much higher frequency was found in the central western, northwestern and southeastern high‐risk regions (Guellouz et al., [2010](#mgg3392-bib-0100){ref-type="ref"}). In Tunisia, the G6PD\*A‐ or Matera variant (c.202G\>A; p.Val68Met) is the most prevalent among G6PD patients and causes a severe phenotype hemolytic anemia following the ingestion of fava beans. G6PD\*Mediterranean (c.563C\>T; p.Ser188Phe) and the G6PD\*Aures (c.143T\>C; p.lle48Thr) mutations were also present in the population (Daoud et al., [2008](#mgg3392-bib-0080){ref-type="ref"}). GdA‐ and Gd Med constitute 56.8%--89.2% of the molecular spectrum. A recent study found that 67.5% of the deficient population carries the Gd A‐ while only 15% harbor the Md Med allele (Haloui et al., [2016](#mgg3392-bib-0115){ref-type="ref"}; Laouini et al., [2013](#mgg3392-bib-0136){ref-type="ref"}). A newborn screening test was carried on 976 neonates from different regions of the country. The frequency of G6PD deficiency was about 4.4%, mirroring that of hemoglobinopathies estimated at 4.48% (Guellouz et al., [2010](#mgg3392-bib-0100){ref-type="ref"}).

Although known as a rare disorder, Fanconi anemia (FA) occurs at high frequency in Tunisia. The "Tunisian Fanconi Anemia registry (TFAR)" created in 2009 included 142 patients from 118 families diagnosed between 1983 and 2008 of which 86% are consanguineous. Only 19% of these patients received bone marrow transplant. The latter became available in 1999 in one center "Centre tunisien de greffe de moelle osseuse" (Hadiji Mseddi et al., [2012](#mgg3392-bib-0102){ref-type="ref"}) in Tunis.

Fanconi anemia is genetically heterogeneous with different complementation groups reported. In Tunisia, FA group A is the most encountered with a frequency of 94% (Bouchlaka et al., [2003](#mgg3392-bib-0050){ref-type="ref"}). A recent study of 83 families, 74 of them are unrelated, including 95 FA patients, revealed the presence of a common haplotype in 42 patients from 26 families and mostly originating from the South of Tunisia. This haplotype was always associated with the deletion of exon 15 in *FANCA*. Another founder mutation in *FANCA* (c.890_893del in exon 10) was identified in Tunisian Jewish patients (Tamary et al., [2000](#mgg3392-bib-0196){ref-type="ref"}). Identification of founder mutations will provide a rapid and cheap molecular diagnostic tool allowing prenatal testing, genetic counseling, and better bone marrow donor selection. Moreover, an accurate diagnosis is crucial for the choice of therapy; a standard protocol for diagnosis of FA was developed. The chromosomal breakage test allowed the differentiation between mosaic FA patients and non‐FA patients (Talmoudi et al., [2013](#mgg3392-bib-0195){ref-type="ref"}).

10. CONGENITAL MALFORMATIONS {#mgg3392-sec-0011}
============================

The absence of an established national registry makes it hard to have an accurate estimate of occurrences of birth defects in the country. Epidemiological data are scarce and often regional, as studies have been conducted in maternity wards of main hospitals. Furthermore, underdiagnosis due to the limited access to prenatal care in certain areas together with the lack of awareness and access to genetic testing lead to underestimated statistics. Data from Neonatal screening surveys of congenital malformations in liveborn babies revealed a comparable incidence \[3.6% (Chaabouni, Nemsia, Riou, Largueche, & Ferchiou, [1986](#mgg3392-bib-0061){ref-type="ref"}), 3.7% (Khrouf et al., [1986](#mgg3392-bib-0135){ref-type="ref"})\] in different regions of the country.

Numerous studies reporting mutations in genes causing congenital malformations have also been reported in recent years; some of the most prevalent are discussed below.

Congenital heart defects represent a public health problem in a developing country like Tunisia. Some of those go under recognized and result in high mortality rates and heavy economic burdens. A retrospective study of 37,294 births registered between 2010 and 2011 revealed an estimated incidence of congenital heart disease of 6.8 per 1,000 births. The most frequent anomaly was ventricular septal defect (VSD), identified in 31% of cases, while coarctation of the aorta and tetralogy of Fallot were found in 4.3% and 6.2%, respectively. About 23% of the patients died and of those 75% occurred before undergoing surgery (Abid et al., [2014](#mgg3392-bib-0002){ref-type="ref"}). In another recent study of 10,447 newborn cases, the prevalence was estimated at 2.77 per 1,000 live births (Methlouthi et al., [2016](#mgg3392-bib-0161){ref-type="ref"}). A multicenter study is needed to establish an accurate rate.

Neural tube defects are another group of major congenital anomalies with a prevalence of 2.02/10,000 live births in the country. Over a period of 20 years (1991--2011), 769 stillborns with neural tube defects were recorded; 59.5% of the cases were females. Spina bifida was the most frequent (38.9%), followed by anencephaly (22.8%) and encephalocele (17.8%). The consanguinity rate was estimated at 36.7% (Nasri et al., [2014](#mgg3392-bib-0171){ref-type="ref"}). It should be noted that fortification of food products with folate is not mandatory for pregnant women in Tunisia.

Disorders of sex development (DSD) are also prevalent in Tunisia similar to other populations with high incidence of endogamy. Congenital adrenal hyperplasia (CAH) due to 21‐OH hydroxylase deficiency is particularly prevalent; screening of the *CYP21B* gene revealed that the most common pathogenic variant in the Tunisian patients is p.Q318X (Kharrat et al., [2004](#mgg3392-bib-0128){ref-type="ref"}). Molecular analysis of 15 unrelated patients suffering from 11β‐hydroxylase deficiency revealed two homozygous pathogenic variants within the *CYP11B1* gene: p.Q356X and p.G379V. The latter had a prevalence of 73.3% among affected patients (Kharrat et al., [2010](#mgg3392-bib-0129){ref-type="ref"}). More recently, a study of patients with 17β‐HSD3 deficiency, a rare recessive form of 46,XY DSD, revealed genetic heterogeneity. A high carrier frequency of the p.C206X pathogenic variant within the *HSD17B3* gene was found at 1 in 40. All carriers harbored the same haplotype suggestive of a founder effect (Ben Rhouma et al., [2017](#mgg3392-bib-0037){ref-type="ref"}).

Bardet‐Biedl syndrome (BBS) is relatively rare, with an estimated prevalence of 1 in 156,000 (M\'hamdi, Ouertani, Maazoul, & Chaabouni, [2011](#mgg3392-bib-0162){ref-type="ref"}). Mutations were frequently found in *BBS1* (37%) and *BBS2* (18%) (M\'hamdi et al., [2014](#mgg3392-bib-0163){ref-type="ref"}), and founder mutations identified in both *BBS2* and *BBS8* (p.R189X and c.459 + 1G\>A, respectively) (Smaoui et al., [2006](#mgg3392-bib-0192){ref-type="ref"}).

11. CHROMOSOMAL ABNORMALITIES {#mgg3392-sec-0012}
=============================

Increased risk for chromosomal abnormalities is due in part to limited access to family planning, diagnosis and associated services, in addition to childbearing at older maternal ages, teenage marriages in the rural areas, and deficient or absent prenatal screening. Consanguinity does not seem to affect the frequency of aneuploidies in the population. Since 1980, karyotyping is the first line of cytogentic analysis in the country. Currently, in situ hybridization as well as array CGH are available for the detection of constitutional abnormalities. Prenatal diagnosis of 3,110 fetuses revealed an incidence of 4.18% of abnormal karyotypes. Among those, 72% were aneuploidies and 40% were trisomy 21 cases (Chaabouni et al., [2001](#mgg3392-bib-0060){ref-type="ref"}). Today pregnant women are offered noninvasive prenatal testing (NIPT) in the private sector to avoid amniocentesis and chorionic villus sampling (CVS).

The prevalence of Down syndrome in Tunisia is estimated at 0.98 per 1,000 pregnancies (Chelli et al., [2008](#mgg3392-bib-0069){ref-type="ref"}). Analysis of 248 patients with cytogenetically confirmed Down syndrome revealed that 22% of patients are the product of consanguineous marriages, mirroring the consanguinity rate (Kelmemi, Chelly, Kharrat, & Chaabouni, [2015](#mgg3392-bib-0126){ref-type="ref"}).

Cases of Turner syndrome (TS) were also reported in Tunisia. A 21‐year retrospective study showed that 24% of patients with Turner syndrome were diagnosed in adulthood (Elleuch et al., [2010](#mgg3392-bib-0084){ref-type="ref"}) compared to 48% in another study of 89 cases of TS (Kammoun et al., [2008](#mgg3392-bib-0124){ref-type="ref"}). Congenital heart defects were noted in 50% of the patients and autoimmune diseases in 39.1%. Dysmorphic features were observed in 85% of cases, mostly in monosomic patients (45,X) (Elleuch et al., [2010](#mgg3392-bib-0084){ref-type="ref"}).

The occurrence of chromosomal abnormalities in patients with nonobstructive azoospermia and severe oligo‐asthenospermia was estimated at 21.7% and 13.5%, respectively (Ghorbel et al., [2012](#mgg3392-bib-0094){ref-type="ref"}). In a recent study of 476 infertile men, chromosomal abnormalities were identified in about 10.9% of cases. Similarly, abnormal findings were higher in the azoospermia group compared to the severe oligozoospermia group (14.02% and 4.05%, respectively) (Amouri et al., [2014](#mgg3392-bib-0009){ref-type="ref"}).

Several cases with chromosomal disorders are reported in the literature, including aneuploidy, chromosomal rearrangements and microdeletion syndromes (Abdallah‐Bouhjar et al., [2013](#mgg3392-bib-0001){ref-type="ref"}; Bouhjar et al., [2012](#mgg3392-bib-0052){ref-type="ref"}). A recent study of 38 cases of Williams‐Beuren syndrome revealed the presence of dysmorphic features in all patients and cardiovascular anomalies in 66%; while about 8% presented with normal intelligence (Ouertani et al., [2014](#mgg3392-bib-0175){ref-type="ref"}).

12. DEAFNESS {#mgg3392-sec-0013}
============

The high rate of consanguinity contributed to the preponderance of deafness in Tunisia, with a high prevalence of nonsyndromic hearing loss ranging between 2% and 8% in some of the isolates in the northern villages (Ben Arab et al., [2004](#mgg3392-bib-0019){ref-type="ref"}). The AR forms (DFNB) are the most frequent of the prelingual genetic forms representing 80% of the studied cases. Assortative mating resulted in the coexistence of different etiologies of hearing loss disorders along with aminoglycoside ototoxicity (Ben Arab et al., [2004](#mgg3392-bib-0019){ref-type="ref"}).

The high frequency of sensorineural deafness elicited research groups in the country to collect families and to identify the genetic etiology of their deafness in collaboration with other North African and European groups. Several new loci were thus first identified in Tunisian families (Table [1](#mgg3392-tbl-0001){ref-type="table-wrap"}), and many mutations were detected. One of the first loci was DFNB1 (*GJB2*), mapped to Chr13q11‐q12 by linkage analysis performed on two large consanguineous Tunisian families exhibiting AR hearing loss (Guilford et al., [1994](#mgg3392-bib-0101){ref-type="ref"}).

###### 

Deafness genes identified in Tunisian families

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                                                                        Locus                           References
  ------------------------------------------------------------------------------ ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  ARNSHL DFNB1                                                                   Locus mapped to 13q             Guilford et al. ([1994](#mgg3392-bib-0101){ref-type="ref"})

  DFNB2                                                                          *MYO7A*                         Weil et al. ([1997](#mgg3392-bib-0209){ref-type="ref"})

  Pendred syndrome                                                               *SLC26A4*                       Masmoudi, Charfedine, et al. ([2000](#mgg3392-bib-0148){ref-type="ref"})\
                                                                                                                 Charfeddine et al. ([2010](#mgg3392-bib-0066){ref-type="ref"})

  ARNSHL DFNB10                                                                  *TMPRSS3*                       Masmoudi et al. ([2001](#mgg3392-bib-0147){ref-type="ref"})

  Thiamine responsive megaloblastic anemia syndrome with diabetes and deafness   *SLC19A2*                       Gritli et al. ([2001](#mgg3392-bib-0098){ref-type="ref"})

  ARNSHL DFNB32                                                                  1q13.3‐22.1                     Masmoudi et al. ([2003](#mgg3392-bib-0151){ref-type="ref"})

  USH1G                                                                          *SANS*                          Weil et al. ([2003](#mgg3392-bib-0208){ref-type="ref"})\
                                                                                                                 Chakchouk, Ben Said, et al. ([2015](#mgg3392-bib-0064){ref-type="ref"}), Chakchouk, Grati, et al. ([2015](#mgg3392-bib-0065){ref-type="ref"})\
                                                                                                                 Riahi et al. ([2015](#mgg3392-bib-0180){ref-type="ref"})

  ARNSHL DFNB13                                                                  Refined the locus to a 2.2 Mb   Masmoudi et al. ([2004](#mgg3392-bib-0149){ref-type="ref"})

  ARNSHL DFNB66                                                                  Locus mapped to 6q21.2‐22.3     Tlili, Männikkö, et al. ([2005](#mgg3392-bib-0198){ref-type="ref"})

  ARNSHL DFNB31                                                                  *WHRN*                          Tlili, Charfedine, et al. ([2005](#mgg3392-bib-0197){ref-type="ref"})

  Brittle cornea syndrome                                                        Locus mapped on 16q24           Abu et al. ([2006](#mgg3392-bib-0003){ref-type="ref"})

  ARNSHL DFNB63                                                                  11q13.3‐q13.4                   Tlili et al. ([2007](#mgg3392-bib-0199){ref-type="ref"})

  AD deafness DFNA36                                                             *TMC1*                          Tlili et al. ([2008](#mgg3392-bib-0200){ref-type="ref"})

  ARNSHL DFNB7/B11                                                               *TMC1*                          Tlili et al. ([2008](#mgg3392-bib-0200){ref-type="ref"})\
                                                                                                                 Ben Said et al. ([2010](#mgg3392-bib-0040){ref-type="ref"})\
                                                                                                                 Riahi et al. ([2014](#mgg3392-bib-0181){ref-type="ref"})

  USH2                                                                           New locus on 15q                Ben Rebeh, Benzina, et al. ([2008](#mgg3392-bib-0030){ref-type="ref"})

  USH1B                                                                          *MYO7A*                         Ben Rebeh, Morinière, et al. ([2008](#mgg3392-bib-0031){ref-type="ref"})\
                                                                                                                 Riahi et al. ([2015](#mgg3392-bib-0180){ref-type="ref"})\
                                                                                                                 Ben‐Rebeh et al. ([2016](#mgg3392-bib-0046){ref-type="ref"})

  ARNSHL DFNB63                                                                  *LRTOMT*                        Ahmed et al. ([2016](#mgg3392-bib-0046){ref-type="ref"})\
                                                                                                                 Riahi et al. ([2014](#mgg3392-bib-0181){ref-type="ref"})

  ARNSHL DFNB1A                                                                  *GJB2*                          Alemanno et al. ([2009](#mgg3392-bib-0008){ref-type="ref"})\
                                                                                                                 Riahi, Hammami, et al. ([2013](#mgg3392-bib-0183){ref-type="ref"}), Riahi, Zainine, et al. ([2013](#mgg3392-bib-0184){ref-type="ref"})\
                                                                                                                 Trabelsi et al. ([2013](#mgg3392-bib-0202){ref-type="ref"})

  AR retinitis Pigmentosa (ARRP)                                                 *PDE6B*                         Hmani‐Aifa et al. ([2009](#mgg3392-bib-0120){ref-type="ref"})

  ARNSHL DFNB3                                                                   *MYO15A*                        Belguith et al. ([2009](#mgg3392-bib-0018){ref-type="ref"})\
                                                                                                                 Riahi et al. ([2014](#mgg3392-bib-0181){ref-type="ref"})

  Usher syndrome type 2A                                                         *GPR98*                         Hmani‐Aifa et al. ([2009](#mgg3392-bib-0120){ref-type="ref"})

  ARNSHL DFNB80                                                                  Locus mapped to 2p16.1‐p21      Mosrati et al. ([2013](#mgg3392-bib-0166){ref-type="ref"})

  AD DFNA3                                                                       *GJB2*                          Riahi, Hammami, et al. ([2013](#mgg3392-bib-0183){ref-type="ref"}), Riahi, Zainine, et al. ([2013](#mgg3392-bib-0184){ref-type="ref"})

  USH1C                                                                          *USH1C*                         Chakchouk, Ben Said, et al. ([2015](#mgg3392-bib-0064){ref-type="ref"})\
                                                                                                                 Ben‐Rebeh et al. ([2016](#mgg3392-bib-0046){ref-type="ref"})

  ARNSHL DFNB53                                                                  *COL11A2*                       Chakchouk, Grati, et al. ([2015](#mgg3392-bib-0065){ref-type="ref"})

  ARNSHL DFNB66                                                                  *DCDC2a*                        Grati et al. ([2015](#mgg3392-bib-0097){ref-type="ref"})

  ARNSHL DFNB60                                                                  *SLC22A4*                       Ben Said et al. ([2016](#mgg3392-bib-0039){ref-type="ref"})

  USH1F                                                                          *PCDH15*                        Ben‐Rebeh et al. ([2016](#mgg3392-bib-0046){ref-type="ref"})
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARNSHL, autosomal recessive nonsyndromic hearing loss.
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*GJB2* is the gene most frequently involved in AR deafness in Tunisia; causative variants were identified in 39% of families with congenital hearing loss. The most common pathogenic variant was c.35delG, accounting for 35% of the cases and 85.4% of all *GJB2* mutant alleles identified (Riahi, Hammami, et al., [2013](#mgg3392-bib-0183){ref-type="ref"}). The carrier frequency of c.35delG in the general population in Tunisia was reported to be 1.3% (Masmoudi, Elgaied‐Boulila, et al., [2000](#mgg3392-bib-0150){ref-type="ref"}).

Fifty‐eight mutations in 21 different genes have been reported in North African families with hearing loss, all included in the North African DNA Mutation Database (<http://www.tdvd.org/northafrica/affiche.php?alpha=D>). The "North African Deafness Chip", a diagnostic oligonucleotide array using multiplex‐PCR coupled with dual‐color arrayed primer extension and targeting these 58 mutations was developed, allowing rapid, accurate, and cost effective method to screen for common mutations in the region (Chakchouk, Ben Said, et al., [2015](#mgg3392-bib-0064){ref-type="ref"}, Chakchouk, Grati, et al., [2015](#mgg3392-bib-0065){ref-type="ref"}).

Usher syndrome, another clinically and genetically heterogeneous AR disorder is also responsible for deafness although it is underdiagnosed in Tunisia (Adato et al., [1997](#mgg3392-bib-0006){ref-type="ref"}). An extensive ophthalmological examination is needed to detect retinitis pigmentosa and peripheral alterations of the retina in patients with congenital profound deafness. This depends on the availability of electroretinography and OCT imaging which is unfortunately limited to tertiary health centers. This hampers the early diagnosis of Usher syndrome, where cochlear implant in early childhood was proven to be beneficial. Identification of the etiology of hearing loss in young children allows early intervention leading to a better linguistic development, social and cognitive skills.

13. METABOLIC DISORDERS {#mgg3392-sec-0014}
=======================

A metabolic clinic was instituted in 1987 at "La Rabta Hospital" in the capital. The organization of metabolic schools since 1988 further contributed to improved awareness of physicians about inborn metabolic disorders.

A number of studies reporting mutations in genes causing Inborn errors of metabolism have been published (Table [2](#mgg3392-tbl-0002){ref-type="table-wrap"}). Among those, some are believed to be founder mutations, information that is helpful for future premarital counseling and carrier screening (Khedhiri et al., [2012](#mgg3392-bib-0131){ref-type="ref"}). However, metabolic disorders remain under diagnosed in Tunisia. Most of the enzymatic tests are not offered in the country and are sent to European laboratories.

###### 

Reported mutations in some metabolic disorders encountered in Tunisia

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                        Gene        Mutations                                            References
  ------------------------------ ----------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------
  Maple syrup disease (MSUD)     *BCKDHB*\   p.Glu239Gly\                                         Jaafar et al. ([2013](#mgg3392-bib-0122){ref-type="ref"})
                                 *DBT*       c.1333_1336delAATG (aka p.Asn445Ter)                 

  PKU                            *PAH*       p.Leu48Ser\                                          Bercovich et al. ([2008](#mgg3392-bib-0047){ref-type="ref"})\
                                             p.Ser349Pro                                          Weinstein et al. ([1993](#mgg3392-bib-0210){ref-type="ref"})

  Cystinosis                     *CTNS*      Absence of 57Kb del\                                 Chkioua et al. ([2015](#mgg3392-bib-0073){ref-type="ref"})
                                             p.Gly308Arg\                                         
                                             c.771_793del23\                                      
                                             Ex1‐Ex5del; 20Kb del                                 

  MPS I\                         *IDUA*      c.1805delTinsGAACA (aka p.Phe602Ter)\                Laradi et al. ([2005](#mgg3392-bib-0139){ref-type="ref"})\
  Hurler\                                    p.Ile270Ser\                                         Chkioua et al. ([2007](#mgg3392-bib-0075){ref-type="ref"})\
  Hurler‐Scheie                              p.Arg628Ter\                                         Chkioua, Khedhiri, Kassab, et al. ([2011](#mgg3392-bib-0076){ref-type="ref"})\
                                             p.Pro533Arg\                                         Chkioua, Khedhiri, Ben Turkia, et al. ([2011](#mgg3392-bib-0071){ref-type="ref"})
                                             p.Tyr581Ter\                                         
                                             p.Leu578Gln\                                         
                                             p.Phe177Ser\                                         
                                             c.1587_1588insGC (aka p.Leu530ArgfsX31)              

  MPS II\                        *IDS*       p.Arg88Pro                                           Chkioua, Khedhiri, Ferchichi, et al. ([2011](#mgg3392-bib-0072){ref-type="ref"})
  Hunter                                                                                          

  Sanfilippo Syndrome MPSIIIA    *SGSH*      p.Met1?\                                             Ouesleti et al. ([2011](#mgg3392-bib-0177){ref-type="ref"})
                                             p.Ser66Trp\                                          
                                             p.Arg377Cys\                                         
                                             p.Gln365Ter\                                         
                                             c.29dupC (p.Leu11AlafsX22)\                          
                                             c.1080delC (aka p.Val361SerfsX52)\                   
                                             Ex1‐Ex5del                                           

  MPSIIIB                        *NAGLU*     p.Tyr558Ter\                                         Ouesleti et al. ([2011](#mgg3392-bib-0177){ref-type="ref"})
                                             p.Pro604Leu (Founder)                                

  MPSIIIC                        *HGSNAT*    p.Trp403Ter (Founder)\                               Ouesleti et al. ([2011](#mgg3392-bib-0177){ref-type="ref"})
                                             p.Tyr627Cys (Vus)                                    

  MPS IV\                        *GALNS*     c.120 + 1G\>A\                                       Khedhiri et al. ([2007](#mgg3392-bib-0132){ref-type="ref"})\
  Morquio A                                  p.Gly66Arg\                                          Khedhiri et al. ([2009](#mgg3392-bib-0130){ref-type="ref"})\
                                             p.Ala85Thr\                                          Khedhiri, Chkioua, Ferchichi, Miled, and Laradi ([2011](#mgg3392-bib-0133){ref-type="ref"})\
                                             p.Asp288Gly\                                         Khedhiri et al. ([2012](#mgg3392-bib-0131){ref-type="ref"})\
                                             p.Arg386Cys                                          Chkioua et al. ([2016](#mgg3392-bib-0074){ref-type="ref"})

  Gaucher disease                *GBA*       p.Asn370Ser\                                         Cherif et al. ([2009](#mgg3392-bib-0070){ref-type="ref"})
                                             p.Leu444Pro (aka Leu483Pro)\                         
                                             RecNciI                                              

  Metachromatic leukodystrophy   *ARSA*      p.Ile179Ser (aka p.Ile181Ser)                        Barboura et al. ([2011](#mgg3392-bib-0015){ref-type="ref"})

  Primary hyperoxaluria          *AGXT*      p.Pro11Leu (DFP)\                                    M\'Dimegh et al. ([2016](#mgg3392-bib-0153){ref-type="ref"})\
                                             p.Pro28Ser\                                          M\'Dimegh et al. ([2017](#mgg3392-bib-0154){ref-type="ref"})\
                                             p.Gly41Arg\                                          Kanoun et al. ([2017](#mgg3392-bib-0125){ref-type="ref"})
                                             p.Ile56Asn\                                          
                                             p.Gly82Arg\                                          
                                             p.Gly190Arg\                                         
                                             p.Gly156Arg\                                         
                                             p.Trp108Arg\                                         
                                             p.Ser205Leu\                                         
                                             p.Ile244Thr\                                         
                                             p.Arg360Gln\                                         
                                             c.33dupC (aka p.Lys12GlnfsX156) c.406_410dupCTGCA\   
                                             aka p.Gln137HisfsX19)                                

  Tyrosinemia type I             *FAH*       c.554‐1G\>T aka\                                     Nasrallah et al. ([2015](#mgg3392-bib-0170){ref-type="ref"})
                                             IVS6‐1G\>T (hot spot)                                

  Tysosinemia type II            *TAT*       p.Cys151Tyr\                                         Charfeddine et al. ([2006](#mgg3392-bib-0067){ref-type="ref"})\
                                             p.Leu273Pro\                                         Bouyacoub et al. ([2013](#mgg3392-bib-0056){ref-type="ref"})
                                             c.869dupG (p.Trp291LeufsX6)                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Maple syrup urine disease (MSUD) is one of the most common disorders of amino acid metabolism in Tunisia, with a reported incidence of 1 in 13,716 live births (Hadj‐Taieb et al., [2012](#mgg3392-bib-0105){ref-type="ref"}). Founder mutations were identified in families originating from central Tunisia (Jaafar et al., [2013](#mgg3392-bib-0122){ref-type="ref"}; Nagara et al., [2014](#mgg3392-bib-0168){ref-type="ref"}).

The frequency of phenylketonuria (PKU) was estimated at 1.32% based on screening of mentally retarded patients originating from different centers throughout the country (Khemir et al., [2009](#mgg3392-bib-0134){ref-type="ref"}). The birth prevalence of congenital hypothyroidism was about 1 in 5,000 based on the data collected between 1996 and 1997 (Chaabouni‐Bouhamed, [2008](#mgg3392-bib-0062){ref-type="ref"}). The incidence of Hereditary Tyrosinemia type 1 is relatively high in Tunisia, and was estimated at 1/14,804 births with a predominance of the chronic form (Nasrallah et al., [2015](#mgg3392-bib-0170){ref-type="ref"}).

Based on a retrospective epidemiological survey of biochemically confirmed cases of Mucopolysaccharidoses (MPS) in Tunisia, collected over a period of 35 years, the incidence was estimated at 1 in 44,000 live births. Consanguinity was found in 83% of the affected families. MPS I and III were the most frequent among the affected individuals (Ben Turkia et al., [2009](#mgg3392-bib-0043){ref-type="ref"}). In the center and south of Tunisia, the incidence of MPS IVA (Morquio) is estimated at 2.8 in 100,000 live births (Laradi et al., [2001](#mgg3392-bib-0138){ref-type="ref"}).

Gaucher disease (GD) is rare in Tunisia and its frequency is estimated at 1:108,000 live births (Dandana, Ben Khelifa, Chahed, Miled, & Ferchichi, [2016](#mgg3392-bib-0079){ref-type="ref"}). A study of 30 affected individuals with GD revealed that N370S, L444P and RecNciI mutations account for 74% of the total GD alleles identified in Tunisian patients (Cherif et al., [2009](#mgg3392-bib-0070){ref-type="ref"}; Table [2](#mgg3392-tbl-0002){ref-type="table-wrap"}). N370S is the most frequent mutation among Tunisian patients (53%) similar to southern European countries (Ben Rhouma et al., [2012](#mgg3392-bib-0038){ref-type="ref"}). This finding suggests that the N370S mutation has been likely introduced in North Africa during the Roman Empire. It is mainly seen at in a heterozygous state in combination with another mutated allele in trans. The L444P was seen in 16% whereas the complex allele RecNciI was detected in 14% alleles (Cherif et al., [2009](#mgg3392-bib-0070){ref-type="ref"}).

Primary hyperoxaluria type 1 (PH1) is another rare AR disease that is particularly frequent in Tunisia. A high number of patients were diagnosed as adults (48%). A recent study of 146 patients from 135 unrelated families with PH1 and originating from 20 different regions identified consanguinity in 56.8% of the patients. The Maghrebian mutation p.I244T was the most frequently identified (43.4%), and is considered the first cause of PH1 in the country (M\'Dimegh et al., [2017](#mgg3392-bib-0154){ref-type="ref"}). This mutation is associated with individuals of Spanish descent and could have an Iberomaurusian origin. In fact, p.I244T is considered a founder mutation in the Canary Islands with a frequency of 91.6% (Benhaj Mbarek et al., [2011](#mgg3392-bib-0044){ref-type="ref"}). Molecular diagnosis guided the choice of treatment such as pyridoxine as well as the transplantation protocol.

The first molecular diagnosis of nephropathic cystinosis was performed in 2015. Three patients from three unrelated consanguineous families were tested. The common 57 Kb deletion was not present, but two previously reported variants (G308R, c.771_793del) were identified as well as a novel deletion of 20,327 bp. One of the families benefited from prenatal diagnosis and one patient received cysteamine treatment since diagnosis (Chkioua et al., [2015](#mgg3392-bib-0073){ref-type="ref"}).

The incidence of CF is unknown and reported to be low, but no epidemiologic study has been done since 2005. This study included 390 affected children from 383 unrelated families recruited from different parts of the country. F508del was the most common mutation (50.74%), followed by G542X (7.96%), W1282X (6.66%) and N1303K (5.92%) (Messaoud et al., [2005](#mgg3392-bib-0159){ref-type="ref"}) (Table [3](#mgg3392-tbl-0003){ref-type="table-wrap"}). A recent multicenter retrospective study including 33 confirmed CF patients enrolled between 1997 and 2012 was reported. Consanguinity was identified in 47% of these cases, with a higher prevalence of males (70%) and an average age of onset estimated at 6 months. Genetic testing was done in 88% of the patients; 51% of whom carry delta 508 mutation (Halioui‐Louhaichi et al., [2015](#mgg3392-bib-0114){ref-type="ref"}). The first case of prenatal diagnosis was performed in 1994 in the laboratory of biochemistry of Children\'s Hospital in Tunis. A 10‐year experience in prenatal diagnosis of CF in Tunisia was recently published. A panel of 17 most frequent mutations in our population was used, with 90% detection rate. Analyzed samples were either chorionic villus (CVS) or amniotic fluid; maternal cell contamination was concurrently tested using a set of polymorphic microsatellite markers. Similar to previous reports, these data showed that F508del is the most common mutation (51.28%), followed by E1104X (12.82%), N1303K and G542X (8.97%). All the other mutations were detected in less than 7% of the tested individuals (Hadj Fredj et al., [2015](#mgg3392-bib-0104){ref-type="ref"}). No premarital carrier screening is offered for cystic fibrosis, and prenatal diagnosis is mainly restricted to the capital and the big coastal cities. No prevention measures are put in place and therapeutic options are very limited and expensive.

###### 

Most common *CFTR* mutations detected in Tunisia

  ---------------------------------------------------------------------------------------------------------------------------------
  Mutations                                References
  ---------------------------------------- ----------------------------------------------------------------------------------------
  p.Trp19Ter\                              Kerem and Kerem ([1995](#mgg3392-bib-0127){ref-type="ref"})\
  p.Arg74Trp\                              Quint, Lerer, Sagi, and Abeliovich ([2005](#mgg3392-bib-0178){ref-type="ref"})\
  p.Gly85Glu\                              Messaoud et al. ([2005](#mgg3392-bib-0159){ref-type="ref"})\
  p.Tyr122Ter\                             Fredj et al. ([2009](#mgg3392-bib-0092){ref-type="ref"})\
  p.Ile148Thr\                             Boudaya, Fredj, Siala, Bibi, and Messaoud ([2013](#mgg3392-bib-0051){ref-type="ref"})\
  p.Val201Met\                             Hadj Fredj et al. ([2013](#mgg3392-bib-0103){ref-type="ref"})\
  p.Gly542Ter (Phoenician)\                Hadj Fredj et al. ([2015](#mgg3392-bib-0104){ref-type="ref"})\
  p.Thr665Ser\                             Oueslati et al. ([2015](#mgg3392-bib-0176){ref-type="ref"})
  p.Val754Met\                             
  p.Arg785Ter\                             
  p.Leu1043Arg\                            
  p.Arg1066Cys\                            
  p.Glu1104Ter\                            
  p.Arg1158Ter\                            
  p.Phe1166Cys\                            
  p.Ile1203Val\                            
  p.Asp1270Asn (Vus)\                      
  p.Trp1282Ter\                            
  p.Asn1303Lys\                            
  c.273 + 1G\>A aka c.405 + 1G\>A\         
  c.579 + 1G\>T aka c.711 + 1G\>T\         
  c.1521_1523delCTT aka F508del\           
  c.1679 + 5A\>G aka c.1811 + 5A\>G\       
  c.2637_2644del8 aka c.2766del8\          
  c.3598delAinsTCT aka c.3729delAinsTCT\   
  c.3718‐2477C\>T aka c.3849 + 10KbC\>T\   
  c.3889dupT aka c.4016insT\               
  c.4136 + 2T\>G aka c.4268 + 2T\>G        

  ---------------------------------------------------------------------------------------------------------------------------------
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Although newborn screening is not yet established, Tunisia has pilot screening programs that test a portion of the population with the goal to expand to cover all babies.

14. NEUROGENETICS {#mgg3392-sec-0015}
=================

The late professor Mongi Ben Hamida is considered the father of Neurology not only in Tunisia but also in the Maghreb. He founded the National Institute of Neurology in 1973, now the reference center in the North of Tunisia. He was the pioneer in the field of hereditary neuromuscular disorders. The department of neurology at the Institute was the first in Tunisia and North Africa to research the epidemiologic profiles of various neurological diseases and to develop research tools to study some of the most frequently encountered disorders in the country. By establishing an international research collaboration network, his team contributed to mapping and identification of the genetic etiology of a number of neuromuscular diseases.

In 1980, professor Ben Hamida described a new type of severe recessively inherited childhood muscular dystrophy, affecting both males and females in 31 cases from 13 families (Ben Hamida & Marrakchi, [1980](#mgg3392-bib-0025){ref-type="ref"}). He named it "Tunisian severe childhood AR muscular dystrophy" (SCARMD), now referred to as limb girdle muscular dystrophy type 2C (LGMD2C). In 1992, the locus was mapped to Chr13q12 in three highly inbred Tunisian families (Ben Othmane et al., [1992](#mgg3392-bib-0027){ref-type="ref"}). The gene encoding for gamma‐sarcoglycan subunit was later identified, and one homozygous deletion c.521delT was found in all tested patients, indicating a founder effect (Noguchi et al., [1995](#mgg3392-bib-0173){ref-type="ref"}). Although LGMD2C is the most common form in the region, mutations in the other subunits were also identified. The first Tunisian family with beta‐sarcoglycanopathy (LGMD2E) was reported in 1998, a homozygous variant p.R91L was identified (Bönnemann et al., [1998](#mgg3392-bib-0049){ref-type="ref"}). Furthermore, a novel locus for AR limb girdle muscular dystrophy LGMD2I was identified in a large consanguineous Tunisian family, with 13 affected individuals, mapping to chr19q13.3 (Driss et al., [2000](#mgg3392-bib-0081){ref-type="ref"}).

Professor Ben Hamida described eight patients belonging to two large inbred families with selective vitamin E deficiency and a Friedreich ataxia phenotype. Linkage analysis and homozygosity mapping were later performed on a total of three families including 12 affected individuals. Friedreich ataxia with vitamin E deficiency (AVED) locus was thus identified and mapped to Chr8q (Ben Hamida et al., [1993](#mgg3392-bib-0023){ref-type="ref"}). A recent study of a large cohort of 131 Tunisian patients (48 families) showed that 91.7% of the 77 patients molecularly tested were homozygous for the c.744delA mutation in *TTPA* gene, suggesting a founder effect. All patients received vitamin E supplementation as a treatment (El Euch‐Fayache, Bouhlal, Amouri, Feki, & Hentati, [2014](#mgg3392-bib-0082){ref-type="ref"}).

Linkage analysis in a large Tunisian family comprising several members presenting with an AR cerebellar ataxia allowed the mapping of gene locus to chr13q11‐12 (Mrissa et al., [2000](#mgg3392-bib-0167){ref-type="ref"}). The same research group mapped a recessive form of familial amyotrophic lateral sclerosis to chr2q33‐q35 in 10 affected members of an inbred ALS2 Tunisian family (Hentati et al., [1994](#mgg3392-bib-0118){ref-type="ref"}).

The first large Tunisian kindred with Giant axonal neuropathy (GAN) was described in 1990. All patients had a relatively slow course of the disease (Ben Hamida, Hentati, & Ben Hamida, [1990](#mgg3392-bib-0024){ref-type="ref"}). Subsequently, linkage and haplotype analysis in this family together with two other consanguineous families led to mapping of *GAN1* to chr16q24.1 (Ben Hamida et al., [1997](#mgg3392-bib-0022){ref-type="ref"}). This region was further narrowed to a less than 590 KB critical interval (Cavalier et al., [2000](#mgg3392-bib-0059){ref-type="ref"}). The *GAN* gene was later identified in collaboration with a French group, confirming the power of homozygosity mapping in such consanguineous families (Bomont et al., [2000](#mgg3392-bib-0048){ref-type="ref"}).

Linkage analysis of a large Tunisian family with 13 out of the 19 affected members presenting with severe axonal AR form of Charcot‐Marie‐Tooth disease with pyramidal features, led to the identification of a new locus CMT4C2 on Chr8q21.3 (Barhoumi et al., [2001](#mgg3392-bib-0016){ref-type="ref"}). No responsible gene has been identified yet.

Another locus CMT4A on chr8q13‐q21 was identified in Tunisian inbred families with early age of onset and severe clinical phenotype. Patients presented with an AR demyelinating peripheral neuropathy (Ben Othmane et al., [1993](#mgg3392-bib-0028){ref-type="ref"}). Further positional cloning allowed the identification of *GDAP1* gene, encoding ganglioside‐induced differentiation‐associated protein‐1, as the causative gene in four different Tunisian families. Three different mutations were detected showing allelic heterogeneity in the region (Baxter et al., [2002](#mgg3392-bib-0017){ref-type="ref"}).

Using homozygosity mapping in a large six generation Tunisian family including six individuals with an AR demyelinating hereditary motor and sensory neuropathy, a locus for the AR CMT4B2 with folding myelin sheaths was mapped to chr11p15 (Ben Othmane et al., [1999](#mgg3392-bib-0029){ref-type="ref"}). Later, linkage analysis of one Tunisian family with four affected members and one Moroccan family with three affected members allowed the identification of a candidate interval overlapping with the previously mapped CMT4B2 locus. Mutations within the *SBF2* (aka *MTMR13*) were identified (Azzedine et al., [2003](#mgg3392-bib-0014){ref-type="ref"}).

In a recent report, a cohort of 100 CMT patients belonging to 57 families collected over 12 years was molecularly analyzed. Among the patients with predominance of demyelinating forms, *PMP22* gene duplication was the most frequent mutation (61.1%) followed by *GDAP1* (22.2%) and *MPZ* gene (11.1%) (Nasri et al., [2015](#mgg3392-bib-0172){ref-type="ref"}).

Genome‐wide screening (6090 SNP markers) of the members of a consanguineous Tunisian family (five affected and eight unaffected) with a complicated HSP‐thin corpus callosum led to the identification of a new locus SPG46 on chromosome 9 (Boukhris et al., [2010](#mgg3392-bib-0054){ref-type="ref"}). Later, mutations in *GBA2* were identified (Hammer et al., [2013](#mgg3392-bib-0116){ref-type="ref"}; Martin et al., [2013](#mgg3392-bib-0146){ref-type="ref"}).

Linkage analysis conducted on eight families where three were from Tunisia allowed the refinement of the SPG15 locus to a 2.64 Mb region as well as the identification of *ZFYVE26* as the causative gene (Boukhris et al., [2008](#mgg3392-bib-0053){ref-type="ref"}; Hanein et al., [2008](#mgg3392-bib-0117){ref-type="ref"}). The minimal prevalence of HSP in the governorate of Sfax was reported to be 5.75/100,000 inhabitants; recessive inheritance was reported in 97.3% of the patients in the region with the high prevalence of complex forms. *SPG11* and *SPG15* constitute the major mutated loci in Tunisia (Boukhris et al., [2009](#mgg3392-bib-0055){ref-type="ref"}).

Familial Parkinsonism is due to mutations within the Leucine---rich repeat kinase 2 (*LRRK2*) gene. The variant p.Gly2019Ser was found to confer a high genotypic and attributable risk (Hulihan et al., [2008](#mgg3392-bib-0121){ref-type="ref"}). Up to 30% of patients with sporadic Parkinson\'s disease carry this variant in Tunisia and 30%--40% in the North African Arab‐Berber population compared to 13% in Ashkenazi Jews and 1% in caucasian populations (Lesage et al., [2006](#mgg3392-bib-0141){ref-type="ref"}; Trinh et al., [2014](#mgg3392-bib-0203){ref-type="ref"}; Warren et al., [2008](#mgg3392-bib-0207){ref-type="ref"}). Incomplete penetrance and variable age of onset were reported. Recently, using genome‐wide linkage analysis on 41 multi‐incident Arab‐Berber families including 253 carriers, followed by locus‐specific association analyses, *DNM3* was identified as an age of onset modifier of the disease (Trinh et al., [2016](#mgg3392-bib-0204){ref-type="ref"}).

There is no formal screening for learning disabilities in Tunisian schools. The undiagnosed prevalence rate of attention deficit disorder (ADHD) reached 10% in the region of Sfax for students between the ages of 6 and 12. Among all the students between the ages of 7 and 9, 8% had undiagnosed learning disabilities (Shaub, [2016](#mgg3392-bib-0191){ref-type="ref"}).

A study of 200 Tunisian boys with mental retardation showed a frequency of 7.6% for Fragile X syndrome cases (Ben Jemaa et al., [2008](#mgg3392-bib-0026){ref-type="ref"}). The prevalence of Fragile X is much higher in the Tunisian Jews due to a founder effect of a rare haplotype consisting of *FMR1* CGG repeats completely devoid of AGG interruptions (Falik‐Zaccai et al., [1997](#mgg3392-bib-0088){ref-type="ref"}; Toledano‐Alhadef et al., [2001](#mgg3392-bib-0201){ref-type="ref"}).

15. XERODERMA PIGMENTOSUM AND OTHER SKIN DISORDERS {#mgg3392-sec-0016}
==================================================

Although a rare disease, many cases with Xeroderma Pigmentosum (XP) were reported in the Tunisian population due to the high rate of consanguineous marriages. The frequency of the disease is estimated to be 1 in 10,000. XP is classified into three clinical forms: severe, intermediate and moderate (Zghal, Fazaa, & Kamoun, [2006](#mgg3392-bib-0212){ref-type="ref"}; Zghal et al., [2003](#mgg3392-bib-0213){ref-type="ref"}). About one‐third of cases are suspected to be XP‐A. XP is associated with an extreme cutaneous photosensitivity, early onset of persistent erythema, DNA repair defects and a high predisposition to cancers. Some patients develop neurological symptoms (Messaoud, Ben Rekaya, Kefi, et al., [2010](#mgg3392-bib-0157){ref-type="ref"}). Molecular diagnosis of XP was introduced in 2007; founder mutations were reported among Tunisian XP patients (Ben Rekaya et al., [2009](#mgg3392-bib-0035){ref-type="ref"}; Messaoud, Ben Rekaya, Cherif, et al., [2010](#mgg3392-bib-0155){ref-type="ref"}). Of 117 XPA alleles harboring p.R228X described so far, 83 were identified in Tunisian patients (Messaoud et al., [2012](#mgg3392-bib-0158){ref-type="ref"}) (Table [4](#mgg3392-tbl-0004){ref-type="table-wrap"}).

###### 

Mutations in XP and other skin disorders

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                 Gene     Mutations                                    References
  ----------------------- -------- -------------------------------------------- ---------------------------------------------------------------------------------------------
  XP‐A                    *XPA*    p.Glu111Ter\                                 Messaoud, Ben Rekaya, et al. ([2013](#mgg3392-bib-0156){ref-type="ref"})\
                                   p.Arg207Ter\                                 Messaoud, Ben Rekaya, Kefi, et al. ([2010](#mgg3392-bib-0157){ref-type="ref"})\
                                   p.Arg228Ter\                                 Messaoud et al. ([2012](#mgg3392-bib-0158){ref-type="ref"})
                                   c.721dupG                                    

  XP‐C                    *XPC*    c.1643_1644delTG (aka p.Val548AlafsX25)\     Ben Rekaya et al. ([2009](#mgg3392-bib-0035){ref-type="ref"})\
                                   c.779 + 1G\>A\                               Messaoud, Laroussi, et al. ([2013](#mgg3392-bib-0160){ref-type="ref"})\
                                   p.Glu284Ter                                  Ben Rekaya et al. ([2013](#mgg3392-bib-0032){ref-type="ref"})\
                                                                                Jerbi et al. ([2016](#mgg3392-bib-0123){ref-type="ref"})

  XP‐V                    *POLH*   Ex10 del\                                    Ben Rekaya et al. ([2014](#mgg3392-bib-0033){ref-type="ref"})\
                                   c.1568_1571delGTCA (aka p.Ser523LysfsX16)\   Ben Rekaya et al. ([2011](#mgg3392-bib-0034){ref-type="ref"})\
                                   c.660 + 1G\>A                                Messaoud, Laroussi, et al. ([2013](#mgg3392-bib-0160){ref-type="ref"})

  Bloom syndrome          *BLM*    c.1985_1986delAA (aka p.Lys662IlefsX5)\      Ben Salah, Salem, Masmoudi, Ben Rhouma, et al. ([2014](#mgg3392-bib-0041){ref-type="ref"})\
                                   c.3620_3621delAA (aka p.Lys1207SerfsX9)      Ben Salah, Salem, Masmoudi, Kallabi, et al. ([2014](#mgg3392-bib-0042){ref-type="ref"})

  Ataxia telangiectasia   *ATM*    p.Arg35Ter (founder)                         Gilad et al. ([1996](#mgg3392-bib-0095){ref-type="ref"})
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Screening of patients with a severe presentation of XP‐C showed genetic homogeneity. One single mutation c.1643_1644delTG was identified, and haplotype analysis suggested a founder effect (Ben Rekaya et al., [2009](#mgg3392-bib-0035){ref-type="ref"}). Moreover, molecular investigation of 64 XP‐C patients belonging to 44 families revealed the presence of the c.1643_1644delTG mutation in 60 patients (94%) (Jerbi et al., [2016](#mgg3392-bib-0123){ref-type="ref"}). A map of the distribution of XP‐C in Tunisia is available; please refer to Jerbi et al., [2016](#mgg3392-bib-0123){ref-type="ref"};. Some clusters of heterogeneity of the disease were recently reported, with the presence of a second founder mutation within exon 7 restricted to the south of the country (Ben Rekaya et al., [2013](#mgg3392-bib-0032){ref-type="ref"}).

Sixteen patients belonging to 10 unrelated families diagnosed with XP‐variant were all found to carry a deletion of exon 10; breakpoints were located within homologous Alu sequences. Screening for this common mutation can be simply done by PCR amplification making molecular testing fast and inexpensive (Ben Rekaya et al., [2014](#mgg3392-bib-0033){ref-type="ref"}).

Recently, whole exome sequencing and Run Of Homozygosity (ROH) analysis were performed for two Tunisian XP patients. This study identified the fisrt cases of complementation groups XP‐D and XP‐E in Tunisia and in North Africa. Pathogenic variants within the *ERCC2* and *DDB2* genes segregated in all affected family members (Ben Rekaya et al., [2017](#mgg3392-bib-0036){ref-type="ref"}).

Xeroderma Pigmentosum strongly predisposes affected individuals to skin cancers including melanoma in areas exposed to sunlight. The incidence of cutaneous melanoma in Tunisia is relatively low and estimated at 0.5--0.7 per 100,000 inhabitants (Naouali et al., [2017](#mgg3392-bib-0169){ref-type="ref"}).

The Northern Tunisian cancer registry consists of four editions that cover a period of 13 years (from 1994 to 2006). The Southern Tunisian cancer registry consists of three editions that cover a period of 6 years (1997--2002).

Since this genodermatosis is relatively common in Tunisia with no available therapy, molecular testing and prenatal diagnosis are very valuable at limiting its occurrence in consanguineous families. Such testing is offered but because of its high cost, only a small number of individuals can benefit from it (Messaoud, Ben Rekaya, et al., [2013](#mgg3392-bib-0156){ref-type="ref"}). A patient support group "Helping Xeroderma Pigmentosum children" was established, providing patients with a better ultraviolet protection (<http://www.xp-tunisie.org.tn>).

Bloom syndrome, another rare autosomal recessive disorder, is relatively frequent in Tunisia. Sister chromatid exchange (SCE) analysis is used to confirm the diagnosis (Ben Salah, Salem, Masmoudi, Ben Rhouma, et al., [2014](#mgg3392-bib-0041){ref-type="ref"}, Ben Salah, Salem, Masmoudi, Kallabi, et al., [2014](#mgg3392-bib-0042){ref-type="ref"}).

16. BREAST AND OVARIAN CANCERS, COLORECTAL CANCER {#mgg3392-sec-0017}
=================================================

The prevalence of breast cancer is between 16% and 38%. Many patients are referred to Salah Azaiz Cancer Institute, where several epidemiological studies have been conducted. The first molecular study of the role of *BRCA1* in hereditary breast cancer identified five different frameshift variants in 5 out of 32 unrelated patients (Troudi et al., [2008](#mgg3392-bib-0205){ref-type="ref"}). A splice site variant specific to the Tunisian population (c.212 + 2insG) was identified in *BRCA1* together with a founder North African mutation c.798_799delTT (Mahfoudh et al., [2012](#mgg3392-bib-0144){ref-type="ref"}). Large rearrangements account for 4%--28% of all inherited *BRCA1/2* mutations. Exon 5 deletion and exon 20 duplication within *BRCA1* gene were identified in Tunisian patients by means of MLPA analysis (Riahi, Chabouni‐Bouhamed, & Kharrat, [2017](#mgg3392-bib-0182){ref-type="ref"}).

Colorectal cancer has an incidence of 7.4 new cases per 100,000 individuals per year. Cases can be either sporadic or more rarely familial. A large deletion involving exon 6 of *MLH1*, a DNA mismatch repair gene, was observed in a family with six patients diagnosed with a colorectal or an endometrial cancer and characterized by a severe phenotype and an early onset (Aissi‐Ben Moussa et al., [2009](#mgg3392-bib-0007){ref-type="ref"}; Chouchane & Hassen, [2010](#mgg3392-bib-0077){ref-type="ref"}).

17. CONCLUSION/FUTURE {#mgg3392-sec-0018}
=====================

There is an urgent need to increase genetic literacy among the health care personnel, in particular primary care practitioners, by providing the appropriate education and training. The lack of public awareness toward the early recognition and prevention of inherited diseases is another hurdle. The public must be informed and educated to seek services and counseling by creating support groups, organizing workshops, and by creating a network between the different care providers, the school or institution and the parents.

18. USEFUL SITES {#mgg3392-sec-0019}
================

<http://www.nationsonline.org/oneworld/tunisia.htm><http://www.africa.upenn.edu/Country_Specific/Tunisia.html><http://www.tunisie.online.fr/><http://www.indexmundi.com/tunisia/#Demographics><https://www.unicef.org/infobycountry/Tunisia_statistics.html><http://en.unesco.org/countries/tunisia><https://data.worldbank.org/country/Tunisia>Washington report on Middle East affairs, Nov/Dec 1996: <http://www.wrmea.org/1996-November-December/tunisia-in-history-the-country-which-gave-its-name-to-a-continent.html><https://fr.wikipedia.org/wiki/Mus%C3%A9e_national_du_Bardo_(Tunisie>)Health and Human rights journal, 12 September 2016: <https://www.hhrjournal.org/2016/09/reproductive-health-policy-in-tunisia-womens-right-to-reproductive-health-and-gender-empowerment/><https://www.oxfordbusinessgroup.com/overview/annual-check-solid-foundation-sector-ready-overhaul>
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